Hodgkin Lymphoma
Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Patrick DalyMyeloma | March 19, 2024
A phase I clinical trial on IDP-023 is currently enrolling patients.
Read More
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 15, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Blood Cancer TalksBlood Cancer Talks | March 20, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | January 4, 2024
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Loretta Nastoupil, MDMeeting News | October 26, 2023
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
Loretta Nastoupil, MDVideo Insights | October 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Blood Cancers Today Staff WritersHodgkin Lymphoma | August 28, 2023
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Cailin ConnerHodgkin Lymphoma | August 10, 2023
The primary objective of the phase II portion was to evaluate the two-year PFS rate with the treatment.
Blood Cancer TalksBlood Cancer Talks | July 19, 2023
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Cecilia BrownPrint | August 17, 2023
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Leah SherwoodHodgkin Lymphoma | February 8, 2024
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
Leah SherwoodMeeting News | June 26, 2023
Multiple regression did not define any independent predictor of response for early evaluation among the baseline parameters.
Cecilia BrownHodgkin Lymphoma | June 13, 2023
Most patients were able to avoid escBEACOPP plus radiotherapy based on PET results.
Chadi Nabhan, MD, MBA, FACPMeeting News | June 7, 2023
The study compared nivolumab plus AVD with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | September 5, 2023
The study showed that nivolumab plus AVD improved PFS over brentuximab vedotin plus AVD.
Cecilia BrownMeeting News | April 20, 2023
BV-AVEPC showed “consistent efficacy” in pediatric patients across age groups “despite lower exposure."
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Cecilia BrownHodgkin Lymphoma | February 7, 2023
Post-AHSCT consolidation with brentuximab vedotin plus nivolumab was “highly active” in relapsed/refractory Hodgkin ...
Editorial Board